Status:
TERMINATED
SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients
Lead Sponsor:
Rabin Medical Center
Conditions:
Leukemia
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Granulocyte colony stimulating factor (G-CSF) is frequently used among patients with cancer including those with haematological malignancies. Filgrastim is a recombinant human CSF whose biological ac...
Detailed Description
Granulocyte colony stimulating factors (G-CSFs) stimulate the proliferation and differentiation of myeloid progenitor cells, improve cell survival and affect some end-cell functions, through binding t...
Eligibility Criteria
Inclusion
- Patients hospitalized in haemato-oncology ward starting filgrastim for the treatment of chemotherapy-induced neutropenia.
- Will include patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), aggressive lymphoma or multiple myeloma.
- Will include both patients with or without a documented infection at the time of CSF initiation. Initiation of filgrastim treatment will follow the 2006 ASCO guidelines (departmental routines).
Exclusion
- The investigators will exclude patients receiving CSFs for their primary disease (e.g. aplastic anemia, myelodysplastic syndromes) and pregnant women.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01222819
Start Date
January 1 2011
End Date
April 1 2013
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center; Beilinson Hospital and Davidoff Cancer Center
Petah Tikva, Israel, 49100